910 Mitochondrial impairment serves as an important biomarker for a range of conditions, including neurological, cardiovascular, infectious, cancerous, and metabolic disorders
For patients seeking modest metabolic support rather than dramatic fat reduction, they may serve a complementary role
The most reliable approach is purchasing from vendors who provide detailed testing documentation, have established reputations in the research community, and demonstrate transparency about their manufacturing and QA processes
Enrollment usually starts with an intake form covering weight, medical history, and current medications
Many treatments are available for cerebral edema and intracranial hypertension
Final results from these trials will likely fuel the expected FDA decision by summer 2026